Patents Assigned to Acticor Biotech
  • Inhibition of platelet aggregation using anti- human gpvi antibodies
    Patent number: 12630631
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: May 19, 2026
    Assignees: ACTICOR BIOTECH, UNIVERSITÉ PARIS CITÉ, UNIVERSITÉ PARIS-XIII, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS-SACLAY
    Inventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
  • TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES
    Publication number: 20250154252
    Abstract: An inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particular an acute ischemic stroke, including the administration of the inhibitor GPVI signaling pathway, in particular the anti-human glycoprotein VI antibody or fragment thereof, to a human patient in need thereof.
    Type: Application
    Filed: February 21, 2023
    Publication date: May 15, 2025
    Applicant: ACTICOR BIOTECH
    Inventors: Gilles AVENARD, Yannick PLETAN, Jean-Marie GROUIN, Sophie BINAY, Elie TOLEDANO, Andrea COMENDUCCI
  • Inhibition of platelet aggregation using anti-human GPVI antibodies
    Patent number: 11692033
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: July 4, 2023
    Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Saclay
    Inventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
  • Anti-human GPVI antibodies and uses thereof
    Patent number: 10842870
    Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 24, 2020
    Assignees: ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAY
    Inventors: Philippe Billiald, Martine Jandrot-Perrus
  • INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES
    Publication number: 20190367608
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Application
    Filed: February 2, 2018
    Publication date: December 5, 2019
    Applicants: Acticor Biotech, Université Paris Diderot - Paris 7, Université Paris-XIII, Nserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Sud 11
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD